Wang Lihui, Zhang Ying, Guo Yanan, Ding Wencui, Chang Ailing, Wei Jing, Li Xinsheng, Qian Hongxia, Zhu Chonggui
Department I of Endocrinology and Diabetes Mellitus, Cangzhou Central Hospital, Cangzhou 061000, Hebei, China.
Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, No. 154 Anshan Road, Heping District, Tianjin 300052, China.
Int J Endocrinol. 2021 Nov 24;2021:4468625. doi: 10.1155/2021/4468625. eCollection 2021.
Diabetic retinopathy (DR) is a prevalent microvascular complication of diabetes, and the levels of chemerin were associated with the severity of DR. However, there is no research on chemerin in the development of proliferative diabetic retinopathy (PDR). Therefore, our study aimed to explore the relationship between chemerin and PDR.
The levels of chemerin/chemokine-like receptor (CMKLR1), proinflammatory cytokines, and vascular endothelial growth factor (VEGF) in 90 cases of PDR and nonproliferative diabetic retinopathy (NPDR) patients and in high glucose (HG) stimulated human retinal pigment epithelium cells (ARPE-19) were evaluated by ELISA. Moreover, chemerin was added into HG-induced ARPE-19 cells to assess its effect on proinflammatory cytokines and VEGF.
The levels of chemerin/CMKLR1 were higher in PDR patients than NPDR ones, and chemerin was positively correlated with CMKLR1 in PDR patients. Compared to NPDR, the secretions of proinflammatory cytokines and VEGF were increased in PDR patients and positively correlated with chemerin/CMKLR1. Additionally, chemerin activated CMKLR1 and aggravated HG-induced cell injury, inflammatory responses, and VEGF expressions in ARPE-19 cells.
Our study demonstrated that chemerin/CMKLR1 axis aggravated the progression of PDR, which suggested that inhibition of chemerin might serve as a new therapeutic approach to treat PDR.
糖尿病视网膜病变（DR）是糖尿病常见的微血管并发症，chemerin水平与DR的严重程度相关。然而，目前尚无关于chemerin在增殖性糖尿病视网膜病变（PDR）发生发展中的研究。因此，我们的研究旨在探讨chemerin与PDR之间的关系。
采用酶联免疫吸附测定法（ELISA）评估90例PDR患者、非增殖性糖尿病视网膜病变（NPDR）患者以及高糖（HG）刺激的人视网膜色素上皮细胞（ARPE-19）中chemerin/趋化因子样受体1（CMKLR1）、促炎细胞因子和血管内皮生长因子（VEGF）的水平。此外，将chemerin加入HG诱导的ARPE-19细胞中，以评估其对促炎细胞因子和VEGF的影响。
PDR患者的chemerin/CMKLR1水平高于NPDR患者，且PDR患者中chemerin与CMKLR1呈正相关。与NPDR相比，PDR患者促炎细胞因子和VEGF的分泌增加，且与chemerin/CMKLR1呈正相关。此外，chemerin激活CMKLR1并加重HG诱导的ARPE-19细胞损伤、炎症反应及VEGF表达。
我们的研究表明chemerin/CMKLR1轴加剧了PDR的进展，这提示抑制chemerin可能成为治疗PDR的一种新的治疗方法。
